Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088140 · ClinicalTrials.gov registry record · Phase 2
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
A Phase 2 study of Hepatitis C, Chronic, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 15
- Study locations
NCT00088140 is a Phase 2 study of Hepatitis C, Chronic that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 204 participants, below the 368-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (45% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT00088140, a Phase 2 study of Hepatitis C, Chronic, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IDN-6556
Study Locations (15)
California
- Scripps Clinic - La Jolla
- California Pacific Medical Center - San Francisco
- University of California, San Francisco - San Francisco
North Carolina
- University of North Carolina - Chapel Hill
- Duke University Medical Center - Durham
Ohio
- University of Cincinnati - Cincinnati
- Metrohealth Medical Center - Cleveland
Arizona
- Mayo Clinic Hospital - Phoenix
Florida
- University of Miami - Miami
Indiana
- Indiana University School of Medicine - Indianapolis
Massachusetts
- Beth Israel Deaconness Medical Center - Boston
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088140
The ClinicalTrials.gov registry entry for NCT00088140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 368-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (45% lower). The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00088140 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT00088140 about?
NCT00088140 is a clinical study titled "A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients". The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
What is the current status of trial NCT00088140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2004-07. Estimated completion is 2005-10.
What conditions does trial NCT00088140 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic.
What interventions are being tested in trial NCT00088140?
The interventions under investigation include: Placebo (DRUG), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT00088140?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00088140 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
-
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
COMPLETED · Phase 2
-
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 2
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
COMPLETED · Phase 2
-
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.